# Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

> **NCT00380302** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 162 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** AVE1625

## Key facts

- **NCT ID:** NCT00380302
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2008-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380302, "Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00380302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*